Drug Trial News

RSS

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.

7 Dec 2015

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).

1 Dec 2015

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study.

1 Dec 2015

Taking estriol along with conventional medications helps RRMS patients avoid relapses

Taking the pregnancy hormone estriol along with their conventional medications helped patients with relapsing-remitting multiple sclerosis (RRMS) avoid relapses, according to results of a Phase II randomized, placebo-controlled study led by UCLA researchers.

1 Dec 2015

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

A large multi-center clinical trial has found that a combination of antiviral medications can eradicate hepatitis C infection in more than 90 percent of patients with advanced liver disease. Known as the ASTRAL-4 trial, the study was co-led by investigators at Beth Israel Deaconess Medical Center and Intermountain Medical Center and published online Nov. 17 in The New England Journal of Medicine.

1 Dec 2015

Researchers examine CR rates in advanced cancer patients who receive cancer treatment

The researchers reported the results of a meta-analysis of 68 chemotherapy trials for cancer treatment between 2000 and 2006 - before the gradual introduction of targeted cancer therapies (drugs that target specific molecular pathways in tumour cells) from 2007, which today can be prescribed alongside cytotoxic drugs.

26 Nov 2015

New drug combination shows promise in treating men with metastatic prostate cancer

A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.

26 Nov 2015

Researchers begin landmark clinical study to restore normal insulin secretion in people with type 1 diabetes

Investigators at Montreal's Lady Davis Institute at the Jewish General Hospital and McGill University Health Centre have announced the start of a landmark clinical study aimed at restoring normal insulin secretion in people with longstanding type 1 diabetes.

26 Nov 2015

New data shows ALS-008176 drug safe and effective against RSV infection

Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies announced that the New England Journal of Medicine will publish findings from a respiratory syncytial virus (RSV) challenge study for ALS-008176, a cytidine nucleoside analog with activity against RSV.

20 Nov 2015

Type II diabetes drug can effectively clear fatty liver disease from some patients

New research published in The Lancet has shown that a drug, currently used in the treatment of Type II diabetes, can be effective in clearing fatty liver disease from some patients.

20 Nov 2015

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.

19 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

New drug combination may reduce need for complex regimens to treat hepatitis C

The prognosis for people with hepatitis C has improved dramatically in the last few years, thanks to the introduction of direct-acting anti-viral medications, including Harvoni (the brand name for a combination of ledipasvir and sofosbuvir) and Viekira Pack (a mix of ombitasvir, paritaprevir, ritonavir and dasabuvir).

19 Nov 2015

Clinical study shows new Ebola vaccine stimulates strong immune responses in adults

A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published in the latest issue of the journal Lancet Infectious Disease.

19 Nov 2015

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Noguchi explained that immunotherapy has emerged recently as a viable and attractive strategy for the treatment of advanced cancer.

18 Nov 2015

Use of azithromycin early reduces risk of recurrent, severe LRTI among young children

Among young children with histories of recurrent severe lower respiratory tract illness (LRTI), the use of azithromycin early during an apparent RTI compared with placebo significantly reduced the risk of experiencing progression to severe LRTI, according to a study in the November 17 issue of JAMA.

18 Nov 2015

Vitamin E shows same efficacy in diabetic and nondiabetic patients

There have been numerous studies on the safety and efficacy of using vitamin E to treat nondiabetic patients with nonalcoholic steatohepatitis (NASH), but researchers at the annual meeting of the American Association for the Study of Liver Diseases presented results of vitamin E in diabetic and nondiabetic patients.

17 Nov 2015

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Drug Trial News

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Taking estriol along with conventional medications helps RRMS patients avoid relapses

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

Researchers examine CR rates in advanced cancer patients who receive cancer treatment

New drug combination shows promise in treating men with metastatic prostate cancer

Researchers begin landmark clinical study to restore normal insulin secretion in people with type 1 diabetes

New data shows ALS-008176 drug safe and effective against RSV infection

Type II diabetes drug can effectively clear fatty liver disease from some patients

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Lilly, Merck expand oncology clinical trial collaboration

New drug combination may reduce need for complex regimens to treat hepatitis C

Clinical study shows new Ebola vaccine stimulates strong immune responses in adults

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Use of azithromycin early reduces risk of recurrent, severe LRTI among young children

Vitamin E shows same efficacy in diabetic and nondiabetic patients

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News